Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment 5. Debunking Myths in the US Healthcare System
Top Ten Searches
aldosteronism contrast dialysis vitamin d bicarbonate arf amyloidosis hypocalcemia renal artery husYour Article Summary
Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Renal Failure, 03/26/08
Shalom R et al. - Hyperuricemia, generally defined as a plasma (or serum) urate concentration >7 mg/dL, has complications like gouty arthritis, nephrolithiasis, and urate or uric acid nephropathy. Allopurinol, or 4-hydroxypirazolo pyrimidine, an analog of xanthine, is used in the treatment of both primary and secondary hyperuricemia. Allopurinol is generally well tolerated, however a life-threatening toxicity syndrome AHS that includes vasculitis, rash, eosinophilia, hepatitis, and progressive renal failure is also described. The term DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) Syndrome has been recently used to describe an entity presenting with similar features.
Today in Chronic Dz/Renal Failure...keeping you current
Receive free subspecialty "5-minute updates" via email
Vitamin D compounds for people with chronic kidney disease not requiring dialysis
Cochrane Reviews, 10/23/09
Nephrogenic systemic fibrosis
Current Opinion in Rheumatology, 11/04/09
Late initiation of renal replacement therapy is associated with worse outcomes in acute kidney injury after major abdominal surgery
Critical Care, 11/06/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis
Kidney International, 11/05/09
Drug dosage protocol for calcium oxalate stone
Urological Research - Urolithiasis, 10/23/09
Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09
Article Search
Sponsor


See Latest Articles


